Research analysts at Leerink Swann began coverage on shares of Endo International (NASDAQ:ENDP) (TSE:ENL) in a research report issued on Tuesday, January 2nd, Marketbeat Ratings reports. The firm set an “outperform” rating and a $12.00 price target on the stock. Leerink Swann’s target price indicates a potential upside of 50.94% from the company’s current price. Leerink Swann also issued estimates for Endo International’s Q4 2017 earnings at $0.57 EPS, FY2017 earnings at $3.65 EPS, Q1 2018 earnings at $0.72 EPS, Q2 2018 earnings at $0.79 EPS, Q3 2018 earnings at $0.76 EPS, Q4 2018 earnings at $0.75 EPS, FY2018 earnings at $3.02 EPS, FY2019 earnings at $3.20 EPS, FY2020 earnings at $2.92 EPS, FY2021 earnings at $2.73 EPS and FY2022 earnings at $2.96 EPS.
Several other brokerages have also recently commented on ENDP. Mizuho reiterated a “buy” rating and set a $14.00 target price (down previously from $19.00) on shares of Endo International in a research report on Tuesday, September 12th. ValuEngine raised shares of Endo International from a “hold” rating to a “buy” rating in a research note on Monday, October 2nd. Goldman Sachs Group assumed coverage on shares of Endo International in a research note on Thursday, September 28th. They issued a “sell” rating and a $7.00 target price for the company. Zacks Investment Research downgraded shares of Endo International from a “buy” rating to a “hold” rating in a research note on Thursday, October 12th. Finally, Piper Jaffray Companies restated a “hold” rating and set a $9.00 price objective on shares of Endo International in a research note on Sunday, September 17th. Three research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $11.27.
Shares of Endo International (NASDAQ ENDP) traded up $0.03 on Tuesday, hitting $7.95. The stock had a trading volume of 4,318,101 shares, compared to its average volume of 5,004,792. The company has a quick ratio of 0.86, a current ratio of 1.08 and a debt-to-equity ratio of 10.78. Endo International has a fifty-two week low of $5.77 and a fifty-two week high of $14.45. The firm has a market cap of $1,768.64, a P/E ratio of -0.35, a P/E/G ratio of 2.72 and a beta of 0.59.
Endo International (NASDAQ:ENDP) (TSE:ENL) last posted its quarterly earnings data on Thursday, November 9th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.85 by $0.06. The firm had revenue of $786.90 million during the quarter, compared to analysts’ expectations of $794.93 million. Endo International had a negative net margin of 126.97% and a positive return on equity of 66.98%. Endo International’s revenue was down 11.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.01 EPS. sell-side analysts anticipate that Endo International will post 3.67 EPS for the current fiscal year.
Large investors have recently modified their holdings of the company. Blair William & Co. IL acquired a new position in shares of Endo International during the second quarter worth $126,000. Riverhead Capital Management LLC lifted its holdings in shares of Endo International by 64.4% during the second quarter. Riverhead Capital Management LLC now owns 15,025 shares of the company’s stock worth $168,000 after purchasing an additional 5,887 shares during the period. Bank of Hawaii acquired a new position in shares of Endo International during the second quarter worth $180,000. LMR Partners LLP acquired a new position in shares of Endo International during the third quarter worth $148,000. Finally, Flinton Capital Management LLC lifted its holdings in shares of Endo International by 64.4% during the second quarter. Flinton Capital Management LLC now owns 20,400 shares of the company’s stock worth $228,000 after purchasing an additional 7,990 shares during the period. Institutional investors own 93.06% of the company’s stock.
WARNING: “Endo International (NASDAQ:ENDP) Receives New Coverage from Analysts at Leerink Swann” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/13/leerink-swann-initiates-coverage-on-endo-international-endp.html.
Endo International Company Profile
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.